

September 19, 2018

**Otsuka Pharmaceutical Factory files patent infringement lawsuit
against AY Pharmaceuticals and Yoshindo**

Otsuka Pharmaceutical Factory, Inc. (Head Office: Naruto, Tokushima, Japan; President and Representative Director: Shinichi Ogasawara; “OPF”) announced that it has filed a patent infringement lawsuit against AY Pharmaceuticals Co., Ltd. and Yoshindo Inc. in Tokyo District Court on September 19, 2018, alleging that ONEPAL[®] No. 1 Injection and ONEPAL[®] No. 2 Injection (glucose, electrolyte, amino acid, vitamin, and trace element injection for central vein infusion) manufactured and distributed by AY Pharmaceuticals and distributed by Yoshindo infringe OPF’s patent (Patent No. 4171216).

The patent covers an invention relating to OPF’s important technology protecting ELNEOPA[®]-NF No. 1 Injection and ELNEOPA[®]-NF No. 2 Injection (glucose, electrolyte, amino acid, multivitamin, and trace element injection for central vein infusion) manufactured and distributed by OPF.

Company Profile

Otsuka Pharmaceutical Factory, Inc.

Established	:	October 7, 1969 (founded September 1, 1921)
Capital	:	80 million yen
Representative	:	Shinichi Ogasawara, President and Representative Director
Head Office	:	115 Kuguhara, Tateiwa, Muya-cho, Naruto, Tokushima 772-8601, Japan
Employees	:	2,297 (as of December 31, 2017)
Scope of Business	:	Manufacture, sale, import and export of clinical nutrition products and other pharmaceutical products, medical devices, functional foods, etc.
Website (URL)	:	https://www.otsukakj.jp/en/